AAAAAA

   
Results: 1-20 |
Results: 20
ADJUVANT CHEMOTHERAPY PLUS ALTERNATED HORMONAL-THERAPY (AVCF-TM) FOR HR-CANCER - 13-YEAR RESULTS OF A RANDOMIZED PHASE-III TRIAL( N+ BREAST)
Authors: DIPALMA M DELALOGE S GUERIN S FARGEOT P CONROY T CHOLLET P MISSET JL
Citation: M. Dipalma et al., ADJUVANT CHEMOTHERAPY PLUS ALTERNATED HORMONAL-THERAPY (AVCF-TM) FOR HR-CANCER - 13-YEAR RESULTS OF A RANDOMIZED PHASE-III TRIAL( N+ BREAST), European journal of cancer, 34, 1998, pp. 104-104
PHASE-III STUDY - TAXOTERE(R) (TXT) VERSUS 5-FLUOROURACIL PLUS NAVELBINE (FUN) IN PATIENTS (PTS) WITH METASTATIC BREAST-CANCER (MBC) AS 2NDLINE CHEMOTHERAPY (CT) (PRELIMINARY-RESULTS)
Authors: MONNIER A BONNETERRE J ROCHE H FARGEOT P NAMER M GUASTALLA JP RIOS M SERIN D CULINE S TUBIANA M EYMARD JC ASSADOURIAN S
Citation: A. Monnier et al., PHASE-III STUDY - TAXOTERE(R) (TXT) VERSUS 5-FLUOROURACIL PLUS NAVELBINE (FUN) IN PATIENTS (PTS) WITH METASTATIC BREAST-CANCER (MBC) AS 2NDLINE CHEMOTHERAPY (CT) (PRELIMINARY-RESULTS), Annals of oncology, 9, 1998, pp. 580-580
AN EORTC-ECSG PHASE-II STUDY OF VINORELBINE IN PATIENTS WITH RECURRENT AND OR METASTATIC SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK/
Authors: DEGARDIN M OLIVEIRA J GEOFFROIS L ROLLAND F ARMAND JP BASTIT P CHAUVERGNE J FARGEOT P VANGLABBEKE M LENTZ MA TRESCA P BOUDILLET J FUMOLEAU P CAPPELAERE P
Citation: M. Degardin et al., AN EORTC-ECSG PHASE-II STUDY OF VINORELBINE IN PATIENTS WITH RECURRENT AND OR METASTATIC SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK/, Annals of oncology, 9(10), 1998, pp. 1103-1107
P53 GENE ALTERATIONS ARE ASSOCIATED WITH A DECREASED RESPONSIVENESS TO NEOADJUVANT CHEMOTHERAPY IN HUMAN BREAST-CANCER
Authors: LIZARDNACOL S COUDERT B RIEDINGER JM FARGEOT P GUERRIN J
Citation: S. Lizardnacol et al., P53 GENE ALTERATIONS ARE ASSOCIATED WITH A DECREASED RESPONSIVENESS TO NEOADJUVANT CHEMOTHERAPY IN HUMAN BREAST-CANCER, International journal of oncology, 10(6), 1997, pp. 1203-1207
IMPLICATION OF THE EPSTEIN-BARR-VIRUS IN THE PROGRESSION OF CHRONIC LYMPHOCYTIC-LEUKEMIA SMALL LYMPHOCYTIC LYMPHOMA TO HODGKIN-LIKE LYMPHOMAS
Authors: PETRELLA T YAZIJI N COLLIN F RIFLE G MORLEVAT F ARNOULD L FARGEOT P DEPRET O
Citation: T. Petrella et al., IMPLICATION OF THE EPSTEIN-BARR-VIRUS IN THE PROGRESSION OF CHRONIC LYMPHOCYTIC-LEUKEMIA SMALL LYMPHOCYTIC LYMPHOMA TO HODGKIN-LIKE LYMPHOMAS, Anticancer research, 17(5B), 1997, pp. 3907-3913
HEPATOID ADENOCARCINOMA OF THE LUNG - REPORT OF A CASE OF AN UNUSUAL ALPHA-FETOPROTEIN-PRODUCING LUNG-TUMOR
Authors: ARNOULD L DROUOT F FARGEOT P BERNARD A FOUCHER P COLLIN F PETRELLA T
Citation: L. Arnould et al., HEPATOID ADENOCARCINOMA OF THE LUNG - REPORT OF A CASE OF AN UNUSUAL ALPHA-FETOPROTEIN-PRODUCING LUNG-TUMOR, The American journal of surgical pathology, 21(9), 1997, pp. 1113-1118
CLINICAL INTEREST OF ESTIMATION OF THE GROWTH-KINETICS OF OVARIAN PRIMARY RECURRENCES BY CA125 DOUBLING TIME
Authors: RIEDINGER JM COUDERT B BARILLOT I BUFFENOIR G MAYER F FARGEOT P CUISENIER J GUERRIN J
Citation: Jm. Riedinger et al., CLINICAL INTEREST OF ESTIMATION OF THE GROWTH-KINETICS OF OVARIAN PRIMARY RECURRENCES BY CA125 DOUBLING TIME, Bulletin du cancer, 84(9), 1997, pp. 855-860
PHASE-II TRIAL OF OXALIPLATIN (L-OHP) IN ADVANCED, RECURRENT AND OR METASTATIC SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK/
Authors: DEGARDIN M CAPPELAERE P KRAKOWSKI I FARGEOT P CUPISSOL D BRIENZA S
Citation: M. Degardin et al., PHASE-II TRIAL OF OXALIPLATIN (L-OHP) IN ADVANCED, RECURRENT AND OR METASTATIC SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK/, European journal of cancer. Part B, Oral oncology, 32B(4), 1996, pp. 278-279
RESULTS OF A PHASE-II TRIAL WITH CYSTEMUSTINE IN ADVANCED MALIGNANT-MELANOMA - A TRIAL OF THE EORTC CLINICAL SCREENING GROUP
Authors: UROSEVIC V CHOLLET P ADENIS A CHAUVERGNE J FARGEOT P ROCHE H KERBRAT P LENTZ MA FUMOLEAU P CHEVALLIER B
Citation: V. Urosevic et al., RESULTS OF A PHASE-II TRIAL WITH CYSTEMUSTINE IN ADVANCED MALIGNANT-MELANOMA - A TRIAL OF THE EORTC CLINICAL SCREENING GROUP, European journal of cancer, 32A(1), 1996, pp. 181-182
ADJUVANT TREATMENT OF NODE-POSITIVE BREAST-CANCER WITH CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL AND VINCRISTINE VERSUS CYCLOPHOSPHAMIDE,METHOTREXATE, AND FLUOROURACIL - FINAL REPORT AFTER A 16-YEAR MEDIAN FOLLOW-UP DURATION
Authors: MISSET JL DIPALMA M DELGADO M PLAGNE R CHOLLET P FUMOLEAU P LEMEVEL B BELPOMME D GUERRIN J FARGEOT P METZ R ITHZAKI M HILL C MATHE G
Citation: Jl. Misset et al., ADJUVANT TREATMENT OF NODE-POSITIVE BREAST-CANCER WITH CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL AND VINCRISTINE VERSUS CYCLOPHOSPHAMIDE,METHOTREXATE, AND FLUOROURACIL - FINAL REPORT AFTER A 16-YEAR MEDIAN FOLLOW-UP DURATION, Journal of clinical oncology, 14(4), 1996, pp. 1136-1145
PROGNOSTIC-SIGNIFICANCE OF THE CA-125 INI TIAL HALF-LIFE MEASURED DURING FIRST-LINE CHEMOTHERAPY IN 62 PATIENTS WITH EPITHELIAL OVARIAN-CANCER STAGE-III OR STAGE-IV
Authors: RIEDINGER JM BARILLOT I COUDERT B FARGEOT P BERRIOLORIEDINGER A GUERRIN J
Citation: Jm. Riedinger et al., PROGNOSTIC-SIGNIFICANCE OF THE CA-125 INI TIAL HALF-LIFE MEASURED DURING FIRST-LINE CHEMOTHERAPY IN 62 PATIENTS WITH EPITHELIAL OVARIAN-CANCER STAGE-III OR STAGE-IV, Bulletin du cancer, 83(8), 1996, pp. 654-663
THERAPEUTIC MONITORING OF 120 HOURS CONTI NUOUS 5-FLUOROURACIL ASSOCIATED WITH CISPLATIN
Authors: COUDERT B DEGISLAIN C BELTRAMO JL GUIGUES B MAYER F BRUCHON Y RIEDINGER JM FARGEOT P DUMAS M GUERRIN J
Citation: B. Coudert et al., THERAPEUTIC MONITORING OF 120 HOURS CONTI NUOUS 5-FLUOROURACIL ASSOCIATED WITH CISPLATIN, Bulletin du cancer, 83(10), 1996, pp. 847-852
FEASIBILITY OF 5-FU THERAPEUTIC MONITORING
Authors: COUDERT B DEGISLAIN C",BELTRAMO,"RIEDINGER JM MAYER F BRUCHON FY DUMAS M FARGEOT P GUERRIN J
Citation: B. Coudert et al., FEASIBILITY OF 5-FU THERAPEUTIC MONITORING, European journal of cancer, 31A, 1995, pp. 966-966
PHASE-II STUDY OF CYSTEMUSTINE IN ADVANCED RENAL-CANCER
Authors: CHAUVERGNE J KERBRAT P ADENIS A CHOLLET P FARGEOT P PUJADELAURAINE E DIERAS V MADELMONT JC LENTZ MA TOULOUSE C CHEVALLIER B
Citation: J. Chauvergne et al., PHASE-II STUDY OF CYSTEMUSTINE IN ADVANCED RENAL-CANCER, European journal of cancer, 31A(1), 1995, pp. 130-131
LENOGRASTIM PREVENTS MORBIDITY FROM INTENSIVE INDUCTION CHEMOTHERAPY IN THE TREATMENT OF INFLAMMATORY BREAST-CANCER
Authors: CHEVALLIER B CHOLLET P MERROUCHE Y ROCHE H FUMOLEAU P KERBRAT P GENOT Y FARGEOT P OLIVIER JP FIZAMES C CLAVEL M YVER A CHABERNAUD VC
Citation: B. Chevallier et al., LENOGRASTIM PREVENTS MORBIDITY FROM INTENSIVE INDUCTION CHEMOTHERAPY IN THE TREATMENT OF INFLAMMATORY BREAST-CANCER, Journal of clinical oncology, 13(7), 1995, pp. 1564-1571
EFFICACY OF LENOGRASTIM ON HEMATOLOGIC TOLERANCE TO MAID CHEMOTHERAPYIN PATIENTS WITH ADVANCED SOFT-TISSUE SARCOMA AND CONSEQUENCES ON TREATMENT DOSE-INTENSITY
Authors: BUI BN CHEVALLIER B CHEVREAU C KRAKOWSKI I PENY AM THYSS A MAUGARDLOUBOUTIN C CUPISSOL D FARGEOT P BONICHON F COINDRE JM GIL B COURCHABERNAUD V
Citation: Bn. Bui et al., EFFICACY OF LENOGRASTIM ON HEMATOLOGIC TOLERANCE TO MAID CHEMOTHERAPYIN PATIENTS WITH ADVANCED SOFT-TISSUE SARCOMA AND CONSEQUENCES ON TREATMENT DOSE-INTENSITY, Journal of clinical oncology, 13(10), 1995, pp. 2629-2636
STANDARDS, OPTIONS AND GUIDELINES FOR THE USE OF ANTIEMETICS IN ONCOLOGY
Authors: RIVIERE A BECKENDORF V BONNETERRE J BUI NB CATIMEL G CUPISSOL D FARGEOT P HECQUET B KRAKOWSKI I MADELAINECHAMBRIN I MIHURA J ROCHE H RUFFIE P SCHNEIDER M PHILIP T
Citation: A. Riviere et al., STANDARDS, OPTIONS AND GUIDELINES FOR THE USE OF ANTIEMETICS IN ONCOLOGY, Bulletin du cancer, 82, 1995, pp. 453-485
ACUTE ANTIEMETIC EFFICACY AND SAFETY OF DOLASETRON MESYLATE, A 5-HT3 ANTAGONISTS, IN CANCER-PATIENTS TREATED WITH CISPLATIN
Authors: CONROY T CAPPELAERE P FABBRO M FAUSER AA SPLINTER TAW SPIELMANN M SCHNEIDER M CHEVALLIER B GOUPIL A CHAUVERGNE J FARGEOT P PREVOT G OGRADY P GREEN D HARDENBERG J BOYCE M
Citation: T. Conroy et al., ACUTE ANTIEMETIC EFFICACY AND SAFETY OF DOLASETRON MESYLATE, A 5-HT3 ANTAGONISTS, IN CANCER-PATIENTS TREATED WITH CISPLATIN, American journal of clinical oncology, 17(2), 1994, pp. 97-102
CLINICAL STAGING VERSUS LAPAROTOMY AND COMBINED-MODALITY WITH MOPP VERSUS ABVD IN EARLY-STAGE HODGKINS-DISEASE - THE H6 TWIN RANDOMIZED TRIALS FROM THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER LYMPHOMA COOPERATIVE GROUP
Authors: CARDE P HAGENBEEK A HAYAT M MONCONDUIT M THOMAS J BURGERS MJV NOORDIJK EM TANGUY A MEERWALDT JH LEFUR R SOMERS R KLUINNELEMANS HC BUSSON A BREED WP BRON D HOLDRINET A RUTTEN EHJM MICHIELS JJ REGNIER R DEBUSSCHER L MUSELLA R FARGEOT P THYSS A CATTAN A RIGALHUGUET F ROTH S CAILLOU B DUPOUY N HENRYAMAR M
Citation: P. Carde et al., CLINICAL STAGING VERSUS LAPAROTOMY AND COMBINED-MODALITY WITH MOPP VERSUS ABVD IN EARLY-STAGE HODGKINS-DISEASE - THE H6 TWIN RANDOMIZED TRIALS FROM THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER LYMPHOMA COOPERATIVE GROUP, Journal of clinical oncology, 11(11), 1993, pp. 2258-2272
NEOADJUVANT CHEMOTHERAPY FOR STAGES IIB-I II CERVICAL CANCERS - LONG-TERM FOLLOW-UP OF PLURICENTRIC RANDOMIZED STUDY OF 151 PATIENTS
Authors: CHAUVERGNE J LHOMME C ROHART J HERON JF AYME Y GOUPIL A FARGEOT P DAVID M
Citation: J. Chauvergne et al., NEOADJUVANT CHEMOTHERAPY FOR STAGES IIB-I II CERVICAL CANCERS - LONG-TERM FOLLOW-UP OF PLURICENTRIC RANDOMIZED STUDY OF 151 PATIENTS, Bulletin du cancer, 80(12), 1993, pp. 1069-1079
Risultati: 1-20 |